Where Mainz Biomed Stands With Analysts
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 4 analysts have published their opinion on Mainz Biomed (NASDAQ:MYNZ) stock, with an average 12-month price target of $14.25, down 28.75% from the previous average of $20.00. The company has received 3 bullish and 1 somewhat bullish ratings.
June 01, 2023 | 6:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Mainz Biomed's average 12-month price target has decreased by 28.75% to $14.25, with 3 bullish and 1 somewhat bullish ratings from 4 analysts over the past 3 months.
The decrease in the average 12-month price target for Mainz Biomed indicates a potential change in market sentiment towards the stock. However, the overall ratings remain positive with 3 bullish and 1 somewhat bullish ratings, suggesting a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100